In HCC, upregulation of PVRL1 stabilizes the surface expression of PVR, which interacts with the inhibitory receptor TIGIT on CD8+ effector memory T cells, suppressing antitumor immune responses and leading to resistance to PD-1 inhibitors [109]. This evidence concerns the gene CD8A and hepatocellular carcinoma.